Anne A Gershon1, David Brooks2, Donald D Stevenson3, William K Chin4, Michael B A Oldstone5, Michael D Gershon6. 1. Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York. 2. Princess Margaret Cancer Center, University of Toronto Medical School, Canada. 3. Viral-Immunobiology Laboratory, Department of Immunology and Microbiology, Scripps Research Institute, La Jolla, California. 4. Allergy, Asthma, Clinical Immunology Clinic, Naval Medical Center Portsmouth, Virginia. 5. Division of Allergy and Immunology, Scripps Clinic Medical Group, La Jolla, California. 6. Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
Abstract
INTRODUCTION: Live attenuated zoster vaccine (Zostavax) was used to test the hypothesis that constitutive level of interleukin 10 (IL-10), which may be high in elderly subjects, impairs vaccine efficacy. If constitutive IL-10 impairs vaccine efficacy, the effectiveness of viral vaccines might be improved by transient inhibition of IL-10 before vaccination. METHODS: Zostavax was given to 26 patients (age, 60-80 years). IL-10 and immunity to varicella zoster virus (VZV) were measured at baseline and after vaccination. Fluorescent antibody to membrane antigen (FAMA) assays and glycoprotein enzyme-linked immunosorbent assays (gpELISAs) were used to assess humoral immunity; anti-varicella virus T-cell responses were studied in a subset of subjects. In a prospective animal model, T-cell responses to chimeric vaccines against lymphocytic choriomeningitis virus (LCMV) were assessed in mice that express or lack IL-10. RESULTS: FAMA assays revealed significant boosting (by 4-fold) of humoral immunity, which occurred only in subjects (10 of 26) with a low constitutive IL-10 level (ie, <20 pg/mL); moreover, the Zostavax-induced FAMA and gpELISA responses were inversely related to the constitutive IL-10 level. Significant VZV-specific T-cell responses followed vaccination only in subjects with a low constitutive IL-10 level. Vaccine-induced LCMV-specific T-cell responses in mice lacking IL-10 were greater than in wild-type animals. CONCLUSIONS: A high constitutive IL-10 level adversely affects vaccine efficacy.
INTRODUCTION: Live attenuated zoster vaccine (Zostavax) was used to test the hypothesis that constitutive level of interleukin 10 (IL-10), which may be high in elderly subjects, impairs vaccine efficacy. If constitutive IL-10 impairs vaccine efficacy, the effectiveness of viral vaccines might be improved by transient inhibition of IL-10 before vaccination. METHODS: Zostavax was given to 26 patients (age, 60-80 years). IL-10 and immunity to varicella zoster virus (VZV) were measured at baseline and after vaccination. Fluorescent antibody to membrane antigen (FAMA) assays and glycoprotein enzyme-linked immunosorbent assays (gpELISAs) were used to assess humoral immunity; anti-varicella virus T-cell responses were studied in a subset of subjects. In a prospective animal model, T-cell responses to chimeric vaccines against lymphocytic choriomeningitis virus (LCMV) were assessed in mice that express or lack IL-10. RESULTS: FAMA assays revealed significant boosting (by 4-fold) of humoral immunity, which occurred only in subjects (10 of 26) with a low constitutive IL-10 level (ie, <20 pg/mL); moreover, the Zostavax-induced FAMA and gpELISA responses were inversely related to the constitutive IL-10 level. Significant VZV-specific T-cell responses followed vaccination only in subjects with a low constitutive IL-10 level. Vaccine-induced LCMV-specific T-cell responses in mice lacking IL-10 were greater than in wild-type animals. CONCLUSIONS: A high constitutive IL-10 level adversely affects vaccine efficacy.
Authors: Daniel L Popkin; John R Teijaro; Andrew M Lee; Hanna Lewicki; Sebastien Emonet; Juan Carlos de la Torre; Michael Oldstone Journal: J Virol Date: 2011-05-25 Impact factor: 5.103
Authors: David G Brooks; Sang-Jun Ha; Heidi Elsaesser; Arlene H Sharpe; Gordon J Freeman; Michael B A Oldstone Journal: Proc Natl Acad Sci U S A Date: 2008-12-15 Impact factor: 11.205
Authors: David G Brooks; Andrew M Lee; Heidi Elsaesser; Dorian B McGavern; Michael B A Oldstone Journal: J Exp Med Date: 2008-03-10 Impact factor: 14.307
Authors: Alessandro Sette; Alba Grifoni; Hannah Voic; Rory D de Vries; John Sidney; Paul Rubiro; Erin Moore; Elizabeth Phillips; Simon Mallal; Brittany Schwan; Daniela Weiskopf Journal: J Virol Date: 2020-11-23 Impact factor: 5.103
Authors: Miguel Junior Sordi Bortolini; Bernardo Petriz; José Roberto Mineo; Rafael de Oliveira Resende Journal: Int J Environ Res Public Health Date: 2022-02-07 Impact factor: 3.390